Table of Contents Author Guidelines Submit a Manuscript
Advances in Virology
Volume 2015, Article ID 616898, 5 pages
http://dx.doi.org/10.1155/2015/616898
Research Article

Comparison of β-Propiolactone and Formalin Inactivation on Antigenicity and Immune Response of West Nile Virus

1Arbovirology Group, Entomology and Filariasis Division, Regional Medical Research Centre, ICMR, Northeast Region, Post Box No. 105, Dibrugarh, Assam 786001, India
2Department of Biotechnology, Tocklai Tea Research Institute, TRA, Jorhat, Assam 785008, India

Received 31 May 2015; Revised 30 July 2015; Accepted 18 August 2015

Academic Editor: Trudy Morrison

Copyright © 2015 Pritom Chowdhury et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. L. Campbell, A. A. Marfin, R. S. Lanciotti, and D. J. Gubler, “West Nile virus,” Lancet Infectious Diseases, vol. 2, no. 9, pp. 519–529, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. Hubálek and J. Halouzka, “West Nile fever—a reemerging mosquito-borne viral disease in Europe,” Emerging Infectious Diseases, vol. 5, no. 5, pp. 643–650, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. E. B. Hayes, J. J. Sejvar, S. R. Zaki, R. S. Lanciotti, A. V. Bode, and G. L. Campbell, “Virology, pathology, and clinical manifestations of West Nile virus disease,” Emerging Infectious Diseases, vol. 11, no. 8, pp. 1174–1179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Murgue, H. Zeller, and V. Deubel, “The ecology and epidemiology of West Nile virus in Africa, Europe and Asia,” Current Topics in Microbiology and Immunology, vol. 267, pp. 195–221, 2002. View at Google Scholar · View at Scopus
  5. A. Papa, P. Perperidou, A. Tzouli, and C. Castilletti, “West Nile virus-neutralizing antibodies in humans in Greece,” Vector-Borne and Zoonotic Diseases, vol. 10, no. 7, pp. 655–658, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. D. Banker, “Preliminary observations on antibody patterns against certain viruses among inhabitants of Bombay city,” Indian Journal of Medical Science, vol. 6, pp. 733–766, 1952. View at Google Scholar
  7. S. R. Paramasivan, A. C. Mishra, and D. T. Mourya, “West Nile virus: the Indian scenario,” Indian Journal of Medical Research, vol. 118, pp. 101–108, 2003. View at Google Scholar · View at Scopus
  8. S. A. Khan, P. Dutta, A. M. Khan et al., “West nile virus infection, Assam, India,” Emerging Infectious Diseases, vol. 17, no. 5, pp. 947–948, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. L. R. Petersen and J. T. Roehrig, “West Nile virus: a reemerging global pathogen,” Emerging Infectious Diseases, vol. 7, no. 4, pp. 611–614, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Posadas-Herrera, S. Inoue, I. Fuke et al., “Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate,” Vaccine, vol. 28, no. 50, pp. 7939–7946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Biedenbender, J. Bevilacqua, A. M. Gregg, M. Watson, and G. Dayan, “Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults,” Journal of Infectious Diseases, vol. 203, no. 1, pp. 75–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. E. I. Budowsky, E. A. Friedman, and N. V. Zheleznova, “Principles of selective inactivation of viral genome. VII. Some peculiarities in determination of viral suspension infectivity during inactivation by chemical agents,” Vaccine, vol. 9, no. 7, pp. 473–476, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. International Agency for Research on Cancer, Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man, World Health Organization, Geneva, Switzerland, 2012.
  14. G. A. Logrippo and F. W. Hartman, “Antigenicity of β-propiolactone-inactivated virus vaccines,” The Journal of Immunology, vol. 75, no. 2, pp. 123–128, 1955. View at Google Scholar
  15. P. Chowdhury, S. A. Khan, P. Dutta, R. Topno, and J. Mahanta, “Characterization of West Nile virus (WNV) isolates from Assam, India: insights into the circulating WNV in northeastern India,” Comparative Immunology, Microbiology and Infectious Diseases, vol. 37, no. 1, pp. 39–47, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Cui, D. Counor, D. Shen et al., “Detection of Japanese encephalitis virus antibodies in bats in Southern China,” The American Journal of Tropical Medicine and Hygiene, vol. 78, no. 6, pp. 1007–1011, 2008. View at Google Scholar · View at Scopus
  17. F. A. Rodrigues and K. H. Pavri, Technical Manual, National Institute of Virology, Pune, India, 1972.
  18. V. Pellegrini, N. Fineschi, G. Matteucci et al., “Preparation and immunogenicity of an inactivated hepatitis A vaccine,” Vaccine, vol. 11, no. 3, pp. 383–387, 1993. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Briese, W. G. Glass, and W. I. Lipkin, “Detection of West Nile virus sequences in cerebrospinal fluid,” The Lancet, vol. 355, no. 9215, pp. 1614–1615, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. D. H. Clarke and J. Casals, “Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses,” The American Journal of Tropical Medicine and Hygiene, vol. 7, no. 5, pp. 561–573, 1958. View at Google Scholar · View at Scopus
  21. A. Gajanana, R. Rajendran, V. Thenmozhi, P. P. Samuel, T. F. Tsai, and R. Reuben, “Comparative evaluation of bioassay and ELISA for detection of Japanese encephalitis virus in field collected mosquitos,” The Southeast Asian Journal of Tropical Medicine and Public Health, vol. 26, no. 1, pp. 91–97, 1995. View at Google Scholar · View at Scopus
  22. C. R. A. Fröhner, R. V. Antonio, T. B. Creczynski-Pasa, C. R. M. Barardi, and C. M. O. Simões, “Cytotoxicity and potential antiviral evaluation of violacein produced by Chromobacterium violaceum,” Memorias do Instituto Oswaldo Cruz, vol. 98, no. 6, pp. 843–848, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Chowdhury, S. A. Khan, R. Topno, P. Dutta, R. N. S. Yadav, and J. Mahanta, “Immunogenic potential and protective efficacy of formalin inactivated circulating Indian strain of West Nile virus,” Asian Pacific Journal of Tropical Medicine, vol. 7, no. 12, pp. 946–951, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S. J. Barteling and J. Vreeswijk, “Developments in foot-and-mouth disease vaccines,” Vaccine, vol. 9, no. 2, pp. 75–88, 1991. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Brown, “Review of accidents caused by incomplete inactivation of viruses,” Developments in Biological Standardization, vol. 81, pp. 103–107, 1993. View at Google Scholar · View at Scopus
  26. S. A. Lawrence, “β-propiolactone: viral inactivation in vaccines and plasma,” The PDA Journal of Pharmaceutical Science and Technology, vol. 54, no. 3, pp. 209–217, 2000. View at Google Scholar · View at Scopus
  27. K. Schaff, “Avian diseases: avian encephalomyelitis immunization with inactivated virus,” American Association of Avian Pathologist, vol. 3, no. 3, pp. 245–256, 1959. View at Google Scholar
  28. N. Masuda, T. Ohnishi, S. Kawamoto, M. Monden, and K. Okubo, “Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples,” Nucleic Acids Research, vol. 27, no. 22, pp. 4436–4443, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. S. D. Jiang, D. Pye, and J. C. Cox, “Inactivation of poliovirus with β-propiolactone,” Journal of Biological Standardization, vol. 14, no. 2, pp. 103–109, 1986. View at Publisher · View at Google Scholar · View at Scopus
  30. H. J. M. Jagt, M. L. E. Bekkers, S. A. J. T. van Bommel, P. van der Marel, and C. C. Schrier, “The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test,” Biologicals, vol. 38, no. 1, pp. 128–134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. W. H. Ruigrok, E. A. Hewat, and R. H. Wade, “Low pH deforms the influenza virus envelope,” Journal of General Virology, vol. 73, no. 4, pp. 995–998, 1992. View at Publisher · View at Google Scholar · View at Scopus
  32. J. T. Roehrig, L. A. Staudinger, A. R. Hunt, J. H. Mathews, and C. D. Blair, “Antibody prophylaxis and therapy for flavivirus encephalitis infections,” Annals of the New York Academy of Sciences, vol. 951, pp. 286–297, 2001. View at Google Scholar · View at Scopus
  33. M. Ferguson, D. J. Wood, and P. D. Minor, “Antigenic structure of poliovirus in inactivated vaccines,” Journal of General Virology, vol. 74, no. 4, pp. 685–690, 1993. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Habib, I. Hussain, W. H. Fang, Z. I. Rajput, Z. Z. Yang, and H. Irshad, “Inactivation of infectious bursal disease virus by binary ethylenimine and formalin,” Journal of Zhejiang University Science B, vol. 7, no. 4, pp. 320–323, 2006. View at Publisher · View at Google Scholar · View at Scopus